Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC) (MK-3475-866/KEYNOTE-866)

NCT03924856 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

907

Enrollment

INDUSTRY

Sponsor class

Conditions

Bladder Cancer

Interventions

DRUG: Pembrolizumab
DRUG: Gemcitabine
DRUG: Cisplatin
PROCEDURE: Surgery (radical cystectomy (RC) plus Pelvic Lymph Node Dissection [PLND])
DRUG: Placebo

Sponsor

Merck Sharp & Dohme LLC